This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
== Bibliography == Christiano, A. M., Greenspan, D. S., Hoffman, G. G., Zhang, X., Tamai, Y., Lin, A.N., Dietz, H.C., Hovnanian, A., & Uitto, J (1993). A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa. Nature Genet. 462–66. Toriello, H. V., Glover, T. W., Takahara, K., Byers, P., Miller, D. E., Higgins, J. V., & Greenspan, D. S. (1996). A translocation interrupt the COL5A1 gene in a patient with Ehlers-Danlos syndrome and hypomelanosis of Ito. Nature Genet 13, 361–365. Kessler, E., Takahara, K., Biniaminov, L., Brusel, M., & Greenspan, D. S. (1996). Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science, 271(5247), 360–362. Clark, T. G., Conway, S. J., Scott, I. C., Labosky, P. A., Winnier, G., Bundy, J., Hogan, B. L. M., & Greenspan, D. S. (1999). The mammalian tolloid-like 1 gene, Tll1, is necessary for normal septation and positioning of the heart. Development 126, 2631–2642. Scott, I. C., Blitz, I. L., Pappano, W. N., Maas, S. A., Cho, K. W. Y., & Greenspan, D. S. (2001). Twisted gastrulation homologs are extracellular cofactors in antagonism of BMP signaling. Nature 410, 475–478. Dart, M. L., Jankowska-Gan, E., Huang, G., Roenneburg, D. A., Keller, M. R., Torrealba, J. R., Rhoads, A., Marshall-Case, S., Kim, B., Bobadilla, J. L., Haynes, L. D., Wilkes, D. S., Burlingham, W. J., & Greenspan, D. S. (2010). IL-17-dependent autoimmunity to collagen type V in atherosclerosis. Circ Res 107, 1106–1116. Huang, G., Ge, G., Wang, D., Gopalakrishnan, B., Butz, D. H., Colman, R.
==== Composition ==== During the process of ejaculation, sperm passes through the ejaculatory ducts and mixes with fluids from the seminal vesicles, the prostate, and the bulbourethral glands to form the semen. The seminal vesicles produce a yellowish viscous fluid rich in fructose and other substances that makes up about 70% of human semen. The prostatic secretion, influenced by dihydrotestosterone, is a whitish (sometimes clear), thin fluid containing proteolytic enzymes, citric acid, acid phosphatase and lipids. The bulbourethral glands secrete a clear lubricant into the lumen of the urethra. Sertoli cells, which nurture and support developing spermatocytes, secrete a fluid into seminiferous tubules that helps transport sperm to the genital ducts. The ductuli efferentes possess cuboidal cells with microvilli and lysosomal granules that modify the ductal fluid by reabsorbing some fluid. Once the semen enters the ductus epididymis the principal cells, which contain pinocytotic vessels indicating fluid reabsorption, secrete glycerophosphocholine which most likely inhibits premature capacitation. The accessory genital ducts, the seminal vesicle, prostate glands, and the bulbourethral glands, produce most of the seminal fluid. Seminal plasma of humans contains a complex range of organic and inorganic constituents. The seminal plasma provides a nutritive and protective medium for the spermatozoa during their journey through the female reproductive tract. The normal environment of the vagina is a hostile one (cf.
A study that did not prevent respiratory uptake found that applying 200 mL of hand disinfectant containing 95% w/w ethanol (150 g ethanol total) over the course of 80 minutes in a 3-minutes-on 5-minutes-off pattern resulted in the median BAC among volunteers peaking 30 minutes after the last application at 17.5 mg/L (0.00175%). This BAC roughly corresponds to drinking one gram of pure ethanol. Ethanol is rapidly absorbed through cut or damaged skin, with reports of ethanol intoxication and fatal poisoning. The timing of peak blood concentration varies depends on the type of alcoholic drink:
Fold Type I — aspartate aminotransferase family Fold Type II — tryptophan synthase family Fold Type III — alanine racemase family (TIM-barrel) Fold Type IV — D-amino acid aminotransferase family Fold Type V — glycogen phosphorylase family
=== Patent === Dow Pharmaceuticals filed the patent for Onexton, and the United States Patent and Trademark Office issued the patent on 16 October 2012. On 24 November 2014, the US Food and Drug Administration (FDA) approved the new drug application (NDA) No. 050819 for Onexton, with Dow Pharmaceutical as the holder. The patent is set to expire on 5 August 2029.
Sources: en.wikipedia.org
=== Scotland to England in 1988 === On 1 May 1988, he set off again from John o' Groats, this time walking through the West Highlands, down the Pennine Way and then south to Land's End: a distance of 1,100 miles (1,800 km) in seven weeks. As part of the training for this walk he ran the gruelling Snowdonia Marathon, in a time of 4 hours and 40 minutes. The walk through Scotland and England raised £2,000 for Macmillan Cancer Support.
D* → D + hν For example, A could be luminol and B could be hydrogen peroxide. D would be 3-aminophthalate (3-APA). In theory, one photon of light should be given off for each molecule of reactant. In practice, the yield ("quantum efficiency") is often low owing to side reactions. Chemiluminescence differs from fluorescence or phosphorescence in that the electronic excited state is the product of a chemical reaction rather than of the absorption of a photon. It is the antithesis of a photochemical reaction, in which light is used to drive an endothermic chemical reaction. Instead, here light is generated from a chemically exothermic reaction. The chemiluminescence might be also induced by an electrochemical stimulus and in that case, it is called electrochemiluminescence.
=== Film and television === AAA, la película: sin límite en el tiempo, a 2010 Mexican movie Anbanavan Asaradhavan Adangadhavan, a 2017 Indian Tamil-language movie Associated Argentine Artists (Spanish: Artistas Argentinos Asociados), an Argentine movie distribution company Spearhead from Space, a 1970 Doctor Who serial (production code "AAA")
===== MeSH D08.811.913.050 – acyltransferases (EC 2.3) ===== MeSH D08.811.913.050.080 – acetyl-CoA C-acyltransferase MeSH D08.811.913.050.134 – acetyltransferases MeSH D08.811.913.050.134.029 – acyl-carrier protein s-acetyltransferase MeSH D08.811.913.050.134.060 – acetyl-CoA C-acetyltransferase MeSH D08.811.913.050.134.105 – amino-acid n-acetyltransferase MeSH D08.811.913.050.134.150 – carnitine O-acetyltransferase MeSH D08.811.913.050.134.170 – chloramphenicol o-acetyltransferase MeSH D08.811.913.050.134.180 – choline o-acetyltransferase MeSH D08.811.913.050.134.310 – dihydrolipoyllysine-residue acetyltransferase MeSH D08.811.913.050.134.375 – glucosamine 6-phosphate n-acetyltransferase MeSH D08.811.913.050.134.407 – histone acetyltransferases MeSH D08.811.913.050.134.440 – p300-CBP coactivator family MeSH D08.811.913.050.134.440.249 – creb-binding protein MeSH D08.811.913.050.134.440.600 – e1a-associated p300 protein MeSH D08.811.913.050.134.700 – phosphate acetyltransferase MeSH D08.811.913.050.134.850 – serine O-acetyltransferase MeSH D08.811.913.050.170 – acyl-carrier protein s-malonyltransferase MeSH D08.811.913.050.173 – 1-acylglycerol-3-phosphate O-acyltransferase MeSH D08.811.913.050.175 – 1-acylglycerophosphocholine O-acyltransferase MeSH D08.811.913.050.200 – aminoacyltransferases MeSH D08.811.913.050.200.400 – gamma-glutamylcyclotransferase MeSH D08.811.913.050.200.500 – gamma-glutamyltransferase MeSH D08.811.913.050.200.700 – peptidyl transferases MeSH D08.811.913.050.200.800 – transglutaminases MeSH D08.811.913.050.200.800.300 – factor xiiia MeSH D08.811.913.050.276 – 5-aminolevulinate synthetase MeSH D08.811.913.050.294 – arylalkylamine n-acetyltransferase MeSH D08.811.913.050.313 – arylamine N-acetyltransferase MeSH D08.811.913.050.331 – atp citrate (pro-s)-lyase MeSH D08.811.913.050.350 – carnitine acyltransferases MeSH D08.811.913.050.350.170 – carnitine O-acetyltransferase MeSH D08.811.913.050.350.200 – carnitine o-palmitoyltransferase MeSH D08.811.913.050.368 – citrate (Si)-synthase MeSH D08.811.913.050.387 – diacylglycerol o-acyltransferase MeSH D08.811.913.050.425 – glycerol-3-phosphate O-acyltransferase MeSH D08.811.913.050.600 – homoserine O-succinyltransferase MeSH D08.811.913.050.612 – hydroxymethylglutaryl-CoA synthase MeSH D08.811.913.050.614 – 2-isopropylmalate synthase MeSH D08.811.913.050.618 – malate synthase MeSH D08.811.913.050.622 – 3-oxoacyl-(acyl-carrier-protein) synthase MeSH D08.811.913.050.625 – phosphatidylcholine-sterol O-acyltransferase MeSH D08.811.913.050.646 – retinol O-fatty-acyltransferase MeSH D08.811.913.050.668 – serine C-palmitoyltransferase MeSH D08.811.913.050.712 – sphingosine N-acyltransferase MeSH D08.811.913.050.799 – sterol O-acyltransferase
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.